Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
influenza messenger RNA vaccine (GSK)
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intramuscular
01
Overview
GSK4382276A is an investigational, multivalent messenger RNA (mRNA)-based vaccine developed by GSK in collaboration with CureVac for the prevention of seasonal influenza. The vaccine utilizes CureVac's proprietary second-generation mRNA backbone to deliver mRNA constructs encoding hemagglutinin (HA) antigens from WHO-recommended influenza A and B strains. By leveraging mRNA technology, the vaccine aims to provide a more flexible and potentially more effective alternative to traditional egg-based or cell-based influenza vaccines. Clinical data from Phase 2 studies (NCT06431607, NCT05823974) in healthy younger and older adults showed that the vaccine met its primary immunogenicity and safety endpoints, demonstrating a favorable reactogenicity profile and robust immune responses across multiple formulations. The program is currently advancing into Phase 3 development.
- Other names
- GSK mRNA seasonal influenza vaccineCureVac/GSK influenza mRNA vaccinemRNA-based multivalent seasonal influenza vaccine
02
Targets
BCR (B-cell receptor (BCR) specific for influenza hemagglutinin epitopes)IFIH1 (MDA5)DDX58 (Retinoic acid-inducible gene I protein)TCR (T cell antigen receptor complex)TLR7/8 (Toll-like receptor 7 and Toll-like receptor 8)HA (Hemagglutinin)
Beyond the preview
Go deeper on influenza messenger RNA vaccine (GSK).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on influenza messenger RNA vaccine (GSK).